This product's status changed to Approval withdrawn on 2023.04.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Summary
- Main use
- Nutritional improvement through the provision of essential fatty acids and calories
- Who uses it
- Adults · Children
- Adult dosage
- Infuse intravenously 1∼2 g of fat/kg body weight per day (equivalent to 5∼10 mL of this product). In general, administer the lipid emulsion as slowly as possible. During the first 15 minutes, do not exceed 0.05∼0.1 g of fat/kg body weight per hour (equivalent to 0.25∼0.5 mL of this product). If no significant adverse effects occur, the infusion rate may be increased to 0.15∼0.2 g of fat/kg body weight per hour (equivalent to 0.75∼1.0 mL of this product). Administer for at least 16 hours per day; continuous administration over 24 hours or longer is recommended. Treatment is generally continued for 1∼2 weeks or longer, and may be extended with appropriate monitoring if necessary.
- Children's dosage
- Neonates: Infuse intravenously 2∼3 g of fat/kg body weight per day (equivalent to 10∼15 mL of this product). Up to a maximum of 4 g of fat/kg body weight per day (equivalent to 20 mL of this product) may be administered. Infants: Infuse intravenously 1∼3 g of fat/kg body weight per day (equivalent to 5∼15 mL of this product).
Ingredients
- Importer
- B.Braun Korea Co., Ltd
Efficacy & effects
Nutritional improvement through the provision of essential fatty acids and calories
View approved original textHide original text
This medication is used to improve the nutritional status of patients requiring parenteral nutrition by supplying essential fatty acids and adequate calories.
Dosage and Administration
Adult dosage
Infuse intravenously 1∼2 g of fat/kg body weight per day (equivalent to 5∼10 mL of this product). In general, administer the lipid emulsion as slowly as possible. During the first 15 minutes, do not exceed 0.05∼0.1 g of fat/kg body weight per hour (equivalent to 0.25∼0.5 mL of this product). If no significant adverse effects occur, the infusion rate may be increased to 0.15∼0.2 g of fat/kg body weight per hour (equivalent to 0.75∼1.0 mL of this product). Administer for at least 16 hours per day; continuous administration over 24 hours or longer is recommended. Treatment is generally continued for 1∼2 weeks or longer, and may be extended with appropriate monitoring if necessary.
Children's dosage
Neonates: Infuse intravenously 2∼3 g of fat/kg body weight per day (equivalent to 10∼15 mL of this product). Up to a maximum of 4 g of fat/kg body weight per day (equivalent to 20 mL of this product) may be administered. Infants: Infuse intravenously 1∼3 g of fat/kg body weight per day (equivalent to 5∼15 mL of this product).
Precautions
This medication should be used with great caution when administered to premature infants and low-birth-weight infants, as it may increase plasma free fatty acid levels. It should not be administered to premature infants with severe respiratory diseases, as this may lead to serious complications due to fat accumulation in the pulmonary vasculature. It should not be used in patients with pathological hyperlipidemia, lipid metabolism disorders, ketoacidosis, hypoxia, thrombosis, acute myocardial infarction, or liver disease. It is also contraindicated in pregnant women, and patients with a history of allergic reactions should be observed closely. Caution should be exercised in patients suspected of metabolic acidosis, pulmonary disease, anemia, or fat embolism. During administration, blood tests, liver function tests, and platelet counts should be closely monitored, and administration should be stopped immediately if adverse reactions occur. This medication should be given slowly while carefully monitoring blood lipid levels, as rapid administration can cause fluid imbalance or lung damage. Diabetic patients should be especially cautious, as ketoacidosis may worsen. The safety of this drug in pregnant or nursing women has not been established; it should only be used when absolutely necessary, with thorough monitoring through various tests. In children, especially premature and low-birth-weight infants, due to immature fat excretion capacity, the dosage should be limited, and blood lipid levels should be carefully monitored. In the case of overdose, symptoms such as liver enlargement, anemia, and coagulopathy may appear, and administration should be stopped immediately, followed by appropriate treatment. This medication must be administered exclusively through a peripheral venous infusion, should not be mixed with other medications, and any remaining medication should be discarded. Additionally, it is recommended to administer more than 40% of the total calories along with carbohydrates.
Side effects
Thrombocytopenia, leukopenia, brown pigmentation in the reticuloendothelial system, hepatomegaly, cholestatic jaundice in centrilobular areas, transient increase in liver function tests, dyspnea, congestive hypoventilation, hyperlipidemia, coagulopathy, cyanosis, nausea, vomiting, allergic reactions, headache, flushing, high fever, sweating, chills, drowsiness, chest pain, back pain, dizziness, edema, overload syndrome
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a cool place below 25 degrees Celsius, in a sealed container to avoid contact with air. This will help maintain the effectiveness of the drug.
Appearance and packaging
Appearance
A milky white suspension in a glass container for injection
Package unit
100, 250, 500 milliliters x manufacturer's packaging unit
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.